Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

January 23, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

1-Year Outcomes for Eluvia in Long Lesions

Presentation VIVA 2018

1-Year Outcomes for Eluvia in Long Lesions

Presenter: William A. Gray

November 09, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

News Opinion Editor's Corner TCT 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

September 22, 2018

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

September 20, 2016

News Industry News

Boston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial

February 21, 2016

News Industry News

Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System

August 19, 2015

News Industry News

New Data Evaluating The Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months

April 28, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.